Aaron L Boster
Overview
Explore the profile of Aaron L Boster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
Coles A, Arnold D, Bass A, Boster A, Compston D, Fernandez O, et al.
Ther Adv Neurol Disord
. 2021 May;
14:1756286420982134.
PMID: 34035833
Background: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 consecutive days 12 months later significantly...
2.
Bass A, Arroyo R, Boster A, Boyko A, Eichau S, Ionete C, et al.
Mult Scler Relat Disord
. 2021 Jan;
49:102717.
PMID: 33476880
Background: Alemtuzumab significantly improved clinical and MRI outcomes vs. subcutaneous interferon beta-1a (SC IFNB-1a) in the CARE-MS trials (NCT00530348, NCT00548405), with sustained efficacy in 2 consecutive extensions (NCT00930553, NCT02255656 [TOPAZ])....
3.
Comi G, Alroughani R, Boster A, Bass A, Berkovich R, Fernandez O, et al.
Mult Scler
. 2019 Nov;
26(14):1866-1876.
PMID: 31762387
Background: Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. Objective: To evaluate efficacy and safety of additional alemtuzumab courses in the...
4.
Saulino M, Anderson D, Doble J, Farid R, Gul F, Konrad P, et al.
Neuromodulation
. 2016 Jul;
19(6):632-41.
PMID: 27434299
Introduction: Troubleshooting helps optimize intrathecal baclofen (ITB) therapy in cases of underdose, overdose, and infection. Methods: An expert panel of 21 multidisciplinary physicians currently managing >3200 ITB patients was convened,...
5.
Saulino M, Ivanhoe C, McGuire J, Ridley B, Shilt J, Boster A
Neuromodulation
. 2016 Jul;
19(6):607-15.
PMID: 27434197
Introduction: When spasticity interferes with comfort, function, activities of daily living, mobility, positioning, or caregiver assistance, patients should be considered for intrathecal baclofen (ITB) therapy. Methods: An expert panel consulted...
6.
Boster A, Bennett S, Bilsky G, Gudesblatt M, Koelbel S, McManus M, et al.
Neuromodulation
. 2016 Jul;
19(6):616-22.
PMID: 27434115
Introduction: Intrathecal baclofen (ITB) screening assesses response to a test dose of ITB on spasticity and function and identifies adverse reactions. Method: An expert panel consulted on best practices after...
7.
Boster A, Adair R, Gooch J, Nelson M, Toomer A, Urquidez J, et al.
Neuromodulation
. 2016 Jul;
19(6):623-31.
PMID: 27433993
Introduction: Intrathecal baclofen (ITB) therapy aims to reduce spasticity and provide functional control. Method: An expert panel consulted on best practices. Results: Pump fill and drug delivery can be started...
8.
Boster A, Ford C, Neudorfer O, Gilgun-Sherki Y
Expert Rev Neurother
. 2015 May;
15(6):575-86.
PMID: 25924547
Glatiramer acetate (GA) is approved for relapsing-remitting multiple sclerosis in 57 countries worldwide, with more than 2 million patient-years of exposure and over 20 years of continuous clinical use without...
9.
Orack J, Deleidi M, Pitt D, Mahajan K, Nicholas J, Boster A, et al.
Stem Cells Transl Med
. 2015 Jan;
4(3):252-60.
PMID: 25593207
In recent years, tremendous progress has been made in identifying novel mechanisms and new medications that regulate immune cell function in multiple sclerosis (MS). However, a significant unmet need is...
10.
Nicholas J, Boster A, Racke M
Neurol Clin Pract
. 2013 Nov;
3(5):404-412.
PMID: 24175156
Preliminary studies have suggested that a high salt diet may play a role in the development of autoimmune disease and possibly multiple sclerosis (MS). Promising clinical trial results for 2...